David W Donley
Overview
Explore the profile of David W Donley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fikar P, Alvarez L, Berne L, Cienciala M, Kan C, Kasl H, et al.
PLoS One
. 2024 Dec;
19(12):e0314992.
PMID: 39652549
Biomedicine today is experiencing a shift towards decentralized data collection, which promises enhanced reproducibility and collaboration across diverse laboratory environments. This inter-laboratory study evaluates the performance of biocytometry, a method...
2.
Eaton S, Donley D, Lom B, Stavnezer A
J Undergrad Neurosci Educ
. 2024 Sep;
22(2):A120-A125.
PMID: 39280713
FUN Final Fridays (FFFs) are a professional development effort resulting from a pandemic-inspired virtual pedagogical meeting. Over the past three academic years, Faculty for Undergraduate Neuroscience (FUN) has hosted FFFs...
3.
Donley D
J Undergrad Neurosci Educ
. 2024 Sep;
22(2):A152-A157.
PMID: 39280704
Traditionally, science courses focus on knowledge and practices within specific disciplines. There has long been a call, however, to increase the focus on the nature and process of science as...
4.
Sathyasaikumar K, la Cruz V, Pineda B, Vazquez Cervantes G, Ramirez Ortega D, Donley D, et al.
Antioxidants (Basel)
. 2022 Feb;
11(2).
PMID: 35204197
Kynurenine 3-monooxygenase (KMO), a key player in the kynurenine pathway (KP) of tryptophan degradation, regulates the synthesis of the neuroactive metabolites 3-hydroxykynurenine (3-HK) and kynurenic acid (KYNA). KMO activity has...
5.
Donley D, Realing M, Gigley J, Fox J
PLoS One
. 2021 May;
16(5):e0250606.
PMID: 33989290
Huntington's disease (HD) is a neurodegenerative disorder caused by a dominant CAG-repeat expansion in the huntingtin gene. Microglial activation is a key feature of HD pathology, and is present before...
6.
Donley D, Olson A, Raisbeck M, Fox J, Gigley J
PLoS One
. 2016 Sep;
11(9):e0162404.
PMID: 27611938
Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a polyglutamine-repeat expansion in the huntingtin protein. Activation of the kynurenine pathway of tryptophan degradation is implicated in the pathogenesis...
7.
Saag K, Shane E, Boonen S, Marin F, Donley D, Taylor K, et al.
N Engl J Med
. 2007 Nov;
357(20):2028-39.
PMID: 18003959
Background: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are...
8.
Keaveny T, Donley D, Hoffmann P, Mitlak B, Glass E, San Martin J
J Bone Miner Res
. 2006 Oct;
22(1):149-57.
PMID: 17042738
Unlabelled: FE modeling was used to estimate the biomechanical effects of teriparatide and alendronate on lumbar vertebrae. Both treatments enhanced predicted vertebral strength by increasing average density. This effect was...
9.
Ma Y, Zeng Q, Donley D, Ste-Marie L, Gallagher J, Dalsky G, et al.
J Bone Miner Res
. 2006 Jun;
21(6):855-64.
PMID: 16753016
Unlabelled: Transiliac bone biopsies were obtained from 55 women treated with teriparatide or placebo for 12-24 months. We report direct evidence that modeling bone formation at quiescent surfaces was present...
10.
Krege J, Donley D, Marcus R
N Engl J Med
. 2005 Aug;
353(6):634-5.
PMID: 16094769
No abstract available.